Search Result

Results for "

P2Y14R

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (1) Angiotensin-converting Enzyme (ACE) (1) Bacterial (3) Dipeptidyl Peptidase (1) Drug Intermediate (3) ERK (1) GLUT (1) Glycosidase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Lipase (1) MEK (1) Necroptosis (1) NF-κB (1) NOD-like Receptor (NLR) (3) P2X Receptor (1) P2Y Receptor (17) p38 MAPK (1) PKA (1) PPAR (1) Pyroptosis (1) Raf (1) Reference Standards (1) SARS-CoV (1) Succinate Dehydrogenase (3)
By Research Areas:	Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (16) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Amylases (1)

Angiotensin-converting Enzyme (ACE) (1)

Bacterial (3)

Dipeptidyl Peptidase (1)

Drug Intermediate (3)

ERK (1)

GLUT (1)

Glycosidase (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Lipase (1)

MEK (1)

Necroptosis (1)

NF-κB (1)

NOD-like Receptor (NLR) (3)

P2X Receptor (1)

P2Y Receptor (17)

p38 MAPK (1)

PKA (1)

PPAR (1)

Pyroptosis (1)

Raf (1)

Reference Standards (1)

SARS-CoV (1)

Succinate Dehydrogenase (3)

By Research Areas:

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (16)

Metabolic Disease (1)

Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7114A

Chloramphenicol succinate sodium 3 Publications Verification	Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate	Infection Inflammation/Immunology
Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-162661

P2Y14R antagonist 2	P2Y Receptor	Inflammation/Immunology
P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active *P2Y14R* antagonist with an IC₅₀ value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis .

HY-161727

P2Y14R antagonist 1	P2Y Receptor NOD-like Receptor (NLR)	Inflammation/Immunology
P2Y14R antagonist 1 (compound I-17) is a selective *P2Y14R* antagonist with an IC₅₀ of 0.6 nM. It exhibits potent *P2Y14R* antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting *P2Y₁₄R* (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-172226

P2Y14R antagonist 3	P2Y Receptor	Inflammation/Immunology
P2Y14R antagonist 3 (Compound A) is a potent and orally active *P2Y₁₄R* antagonist with an IC₅₀ value of 23.60 nM and a K_d value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases .

HY-173407

P2Y14R antagonist 4	P2Y Receptor Interleukin Related	Inflammation/Immunology
P2Y₁₄R antagonist 4 (Compound 25l) is an orally active *P2Y₁₄R* antagonist (IC₅₀: 5.6 nM) with superior binding affinity to P2Y₁₄R over PPTN. P2Y₁₄R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release .

HY-161343

HDL-16	P2Y Receptor Necroptosis	Inflammation/Immunology
HDL-16 is a potent *P2Y₁₄R* antagonist with an IC₅₀ of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function .

HY-179133

HDB-1	P2Y Receptor PKA Raf MEK ERK	Inflammation/Immunology
HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC₅₀ of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .

HY-156220

MRS4654	P2Y Receptor	Neurological Disease Inflammation/Immunology
MRS4654 is an efficient and neutral *P2Y14R* (hP2Y14R IC₅₀ = 15.0 nM, mP2Y14R IC₅₀ = 18.6 nM) antagonist. MRS4654 has analgesic and anti-inflammatory effects. MRS4654 can be used for research on asthma and neuropathic pain .

HY-143890

MRS4738	P2X Receptor	Cardiovascular Disease Inflammation/Immunology
MRS4738 is a potent and high affinity *P2Y14R* antagonist. MRS4738 exhibits anti-hyperallodynic and antiasthmatic activity in vivo .

HY-N7114

Chloramphenicol succinate	Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase	Infection Inflammation/Immunology
Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-110369

MRS2905 trisodium a,β-Methylene-2-thio-UDP trisodium	P2Y Receptor	Inflammation/Immunology
MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective *P2Y14R* agonist with an EC₅₀ of 0.92 nM. MRS2905 trisodium is inactive at the UDP-activated P2Y6 receptor, and at other P2Y receptors .

HY-170950

P2Y14 antagonist 1	P2Y Receptor NOD-like Receptor (NLR)	Inflammation/Immunology
P2Y14 antagonist 1 (compound 45) is a high selective and orally active *P2Y14R* antagonist with an IC₅₀ of 0.70 nM. P2Y14R antagonist 1 demonstrates significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. P2Y14R antagonist 1 has the potential for the research of acute lung injury .

HY-178006

MRS4917	P2Y Receptor	Neurological Disease
MRS4917 is an orally active, potent selective P2Y₁₄ receptor (hP2Y₁₄R) antagonist (IC₅₀ = 2.88 nM, K_i = 1.67 nM) that shows >18,000 fold selectivity against P2Y₆R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research .

HY-131821

5'-TMPS Thymidine-5'-O-monophosphorothioate	P2Y Receptor	Others
5'-TMPS (Thymidine-5'-O-monophosphorothioate) is a selective partial agonist of P2Y₆R and an antagonist of *P2Y₁₄R*. Additionally, 5'-TMPS acts as a positive regulator of angiogenesis, exhibiting pro-angiogenic effects

HY-167855

MRS4833	P2Y Receptor	Inflammation/Immunology
MRS4833 (compound 15) is an orally active, potent, competitive *P2Y₁₄R* antagonist with an of IC₅₀ of 5.92 nM for hP2Y₁₄R and an IC₅₀ of 4.8 nM for mP2Y₁₄R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

HY-167855S

1’-Epi Gemcitabine hydrochloride-13C,15N2	Isotope-Labeled Compounds P2Y Receptor	Inflammation/Immunology
1’-Epi Gemcitabine hydrochloride- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC₅₀ of 5.92 nM for hP2Y14R and an IC₅₀ of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

HY-N7114AR

Chloramphenicol succinate sodium (Standard)	Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase	Infection Inflammation/Immunology
Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7114A

Chloramphenicol succinate sodium 3 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Metabolic Disease Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate
Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-N8599

Cichoriin 2 Publications Verification	Infection Structural Classification Monophenols other families Classification of Application Fields Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting *P2Y₁₄R* (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-N7114

Chloramphenicol succinate	Structural Classification Microorganisms Antibiotics Disease Research Other Antibiotics Source Classification	Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase
Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

HY-N7114AR

Chloramphenicol succinate sodium (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase
Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a *P2Y14R* inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .

Cat. No.	Product Name	Chemical Structure

HY-167855S

1’-Epi Gemcitabine hydrochloride-13C,15N2
1’-Epi Gemcitabine hydrochloride- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC₅₀ of 5.92 nM for hP2Y14R and an IC₅₀ of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

1’-Epi Gemcitabine hydrochloride-13C,15N2

1’-Epi Gemcitabine hydrochloride- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC₅₀ of 5.92 nM for hP2Y14R and an IC₅₀ of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks